These results emphasize the conclusion that PHLDA1 might be an attractive therapeutic target in breast cancer, pancreatic, gastric adenocarcinoma, and glioma, provided that its expression profile is determined. The gene discussed is PHLDA1; the disease is central nervous system cancer.